This Netgear Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Immunome ( NASDAQ:IMNM ) , Dorman Products ( NASDAQ:DORM )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Wells Fargo analyst David Lantz initiated coverage on Dorman Products, Inc.
Zentalis ( ZNTL ) Q2 Loss Narrows 70%
Zentalis Pharmaceuticals ( NASDAQ:ZNTL ) , a clinical-stage biopharmaceutical company focused on developing cancer therapies, released its second quarter earnings on August 6, 2025. The headline news was a much narrower net loss per share than forecast: it posted a GAAP EPS of $0.37 for Q2 2025, ...
Immunome, Inc. ( IMNM ) Reports Q2 Loss, Beats Revenue Estimates
Immunome (IMNM) delivered earnings and revenue surprises of +3.85% and +62.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Immunome ( IMNM ) Q2 Revenue Surges 382%
Immunome ( NASDAQ:IMNM ) , a clinical-stage biotechnology company developing targeted therapies for cancer, reported its second quarter 2025 earnings on August 6, 2025. The standout news was a substantial revenue beat, with $4.0 million in GAAP revenue topping analyst forecasts by a wide margin, ...
Voyager Therapeutics ( VYGR ) Reports Q2 Loss, Lags Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -18.75% and -55.43%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Absci Corporation ( ABSI ) Expected to Beat Earnings Estimates: Should You Buy?
ABSCI CORP (ABSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jazz Pharmaceuticals ( JAZZ ) Reports Q2 Loss, Misses Revenue Estimates
Jazz (JAZZ) delivered earnings and revenue surprises of -34.80% and -0.26%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
ASP Isotopes Inc. and IsoBio, Inc. Announce Series Seed Funding of IsoBio, Inc. to Advance Innovative Antibody-Isotope Conjugates ( AICsTM ) For Cancer Treatment - Immunome ( NASDAQ:IMNM ) , ASP Isotopes ( NASDAQ:ASPI )
- IsoBio, Inc. ( IsoBio ) is a U.S.-based radiotherapeutic development company focused on developing a broad pipeline of mAb-based radioisotope therapeutics, known as antibody-isotope conjugates ( AICsTM ) , targeting both derisked and novel tumor antigens for patients in need of new cancer ...
ASP Isotopes Inc. and IsoBio, Inc. Announce Series Seed Funding of IsoBio, Inc. to Advance Innovative Antibody-Isotope Conjugates ( AICsTM ) For Cancer Treatment
- IsoBio, Inc. ( IsoBio ) is a U.S.-based radiotherapeutic development company focused on developing a broad pipeline of mAb-based radioisotope therapeutics, known as antibody-isotope conjugates ( AICsTM ) , targeting both derisked and novel tumor antigens for patients in need of new cancer ...
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer - Iovance Biotherapeutics ( NASDAQ:IOVA )
SAN CARLOS, Calif., July 15, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
SAN CARLOS, Calif., July 15, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc. ( NASDAQ: IOVA ) , a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ( TIL ) therapies for patients with cancer, today announced ...
Immunome ( IMNM ) Soars 6.0%: Is Further Upside Left in the Stock?
Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Immunome ( IMNM ) Upgraded to Buy: Here's What You Should Know
Immunome (IMNM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See a 158.17% Upside in Immunome ( IMNM ) : Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 158.2% in Immunome (IMNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think Immunome ( IMNM ) Could Surge 188.57%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 188.6% in Immunome (IMNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
All You Need to Know About Immunome ( IMNM ) Rating Upgrade to Buy
Immunome (IMNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Immunome, Inc. ( IMNM ) Reports Q1 Loss, Tops Revenue Estimates
Immunome (IMNM) delivered earnings and revenue surprises of 21.21% and 28.33%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Bolt Biotherapeutics, Inc. ( BOLT ) Reports Q1 Loss, Tops Revenue Estimates
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of 14.71% and 19.45%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Believe Immunome ( IMNM ) Could Rally 249.93%: Here's is How to Trade
The consensus price target hints at a 249.9% upside potential for Immunome (IMNM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Alnylam ( ALNY ) Moves 8.5% Higher: Will This Strength Last?
Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer ( PROC ...
Immunome, Inc. ( IMNM ) Reports Q4 Loss, Misses Revenue Estimates
Immunome (IMNM) delivered earnings and revenue surprises of -23.53% and 10.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
The Joint Corp. ( JYNT ) Matches Q4 Earnings Estimates
The Joint (JYNT) delivered earnings and revenue surprises of 0% and 50.09%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Urogen Pharma ( URGN ) Reports Q4 Loss, Lags Revenue Estimates
Urogen Pharma (URGN) delivered earnings and revenue surprises of -8.11% and 6.08%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
AbCellera Biologics Inc. ( ABCL ) Reports Q4 Loss, Misses Revenue Estimates
AbCellera Biologics (ABCL) delivered earnings and revenue surprises of 26.67% and 40.83%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Immunome, Inc. ( IMNM ) Reports Q3 Loss, Misses Revenue Estimates
Immunome (IMNM) delivered earnings and revenue surprises of -30% and 19.05%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
ImmunityBio ( IBRX ) Reports Q3 Loss, Tops Revenue Estimates
ImmunityBio (IBRX) delivered earnings and revenue surprises of 22.22% and 39.89%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Cytokinetics ( NASDAQ:CYTK )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Guggenheim analyst Seamus Fernandez initiated coverage on Cidara Therapeutics, Inc.
TELA Bio, Inc. ( TELA ) Reports Q3 Loss, Lags Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of -13.51% and 0.75%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Illumina ( ILMN ) Tops Q3 Earnings and Revenue Estimates
Illumina (ILMN) delivered earnings and revenue surprises of 31.03% and 0.48%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Immunome, Inc. ( IMNM ) Reports Q2 Loss, Misses Revenue Estimates
Immunome (IMNM) delivered earnings and revenue surprises of -28.95% and 9.77%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress
$426.4M cash, cash equivalents and marketable securities as of June 30, 2024. Projected cash runway into ...
Cartesian Therapeutics, Inc. ( RNAC ) Q2 Earnings and Revenues Top Estimates
Cartesian Therapeutics, Inc. (RNAC) delivered earnings and revenue surprises of 166.67% and 457.42%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cytek Biosciences, Inc. ( CTKB ) Reports Q2 Loss, Lags Revenue Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -166.67% and 4.89%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Nectin Therapeutics Licenses Novel Antibodies to Immunome - Immunome ( NASDAQ:IMNM )
- Exclusive worldwide license agreement for antibodies against undisclosed target JERUSALEM, July 25, 2024 /PRNewswire/ -- Nectin Therapeutics, Ltd., a biotechnology company developing novel immunotherapies and antibody drug conjugates ( ADC ) to address tumor resistance, today announced a ...
Immunome Hits 80-Plus Relative Strength Rating Benchmark
On Wednesday, Immunome ( IMNM ) earned an upgrade to its Relative Strength ( RS ) Rating, from 80 to 83.
Immunome Hits 80-Plus Relative Strength Rating Benchmark
One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Immunome ( IMNM ) cleared that benchmark Tuesday, with a jump from 66 to 80 Tuesday.
Over $13M Bet On ProFrac Holding? Check Out These 4 Stocks Insiders Are Buying - Astrotech ( NASDAQ:ASTC )
Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
Immunome, Inc. ( IMNM ) Reports Q1 Loss, Misses Revenue Estimates
Immunome (IMNM) delivered earnings and revenue surprises of 57.50% and 74.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Immunome, Inc. ( IMNM ) to Report a Decline in Earnings: What to Look Out for
Immunome (IMNM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for April 4th
IMNM, SLOIF and TMQ have been added to the Zacks Rank #5 (Strong Sell) List on April 4, 2023.
Company News for Apr 2, 2024
Companies In The News Are: SMTC, OXM, IMNM, GOOGL.
Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What's Driving Markets Thursday? - Agnico Eagle Mines ( NYSE:AEM )
In the final session of the short trading week leading up to Easter festivities, U.S. equity indices held steady, reflecting some setbacks in market expectations regarding interest rate reductions. On Wednesday, Fed Governor Christopher J.
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
MONMOUTH JUNCTION, N.J., March 26, 2024 ( GLOBE NEWSWIRE ) -- Ayala Pharmaceuticals, Inc. ( OTCQX: ADXS ) , a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. ( Nasdaq: IMNM ) .
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday - FedEx ( NYSE:FDX ) , Worthington Steel ( NYSE:WS )
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday. Shares of Worthington Steel, Inc. WS rose sharply during Friday's session as the company posted stronger-than-expected results for its third quarter.
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors - Immunome ( NASDAQ:IMNM ) , Shattuck Labs ( NASDAQ:STTK )
AUSTIN, TX and DURHAM, NC, March 04, 2024 ( GLOBE NEWSWIRE ) -- Shattuck Labs, Inc. ( Shattuck ) STTK, a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune ...
Biotech Stocks Surge To Start 2024: 'Charts Look Great,' But Will The Trend Continue? - SPDR Series Trust SPDR S&P Biotech ETF ( ARCA:XBI )
The biotech sector has been surging in recent months, reawakening from a period of underperformance that followed the 2021 highs. David Prince, professional trader at T3 Trading Group, joined Benzinga's "PreMarket Prep" on Tuesday and discussed the biotech industry, highlighting Viking ...
Immunome ( IMNM ) to Acquire Desmoid Tumor Candidate, Stock Up
Immunome (IMNM) inks an asset purchase agreement with Ayala Pharmaceuticals to acquire the latter's investigational candidate, AL102, being developed for treating desmoid tumors. Stock rises.
Why VCI Global Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving Premarket - Atreca ( NASDAQ:BCEL ) , Aeries Technology ( NASDAQ:AERT )
Shares of VCI Global Limited VCIG fell sharply in pre-market trading after the company announced pricing of $2.75 million public offering. VCI Global shares tumbled 29.5% to $1.10 in pre-market trading Here are some other stocks moving in pre-market trading. Volcon, Inc.
US Stocks Higher; Inflation Rate Increases To 3.4% In December - 180 Life Sciences ( NASDAQ:ATNF ) , Atreca ( NASDAQ:BCEL )
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 50 points on Thursday. Following the market opening Thursday, the Dow traded up 0.07% to 37,723.53 while the NASDAQ rose 0.46% to 15,039.09. The S&P 500 also rose, gaining, 0.21% to 4,793.32.
